eNeura, Inc., a privately held medical technology company developing non-invasive, non-drug treatment and prevention of migraine headache, announced today that it had completed a Series D financing, led by Camden Partners Nexus, an investment group based in Baltimore, Maryland. A variety of local investors participated in the round, including the Abell Foundation, serial entrepreneur David Oros, Marc Blum, and the Fischell family, who also founded the company. The proceeds of the Series D financing will be used for the commercial expansion of the company’s sTMS mini neuromodulation device for the acute treatment and prevention of migraine.

“In the past, migraine patients in the U.S. have had to depend on combinations of pharmaceutical products, each with potentially unpleasant side-effects, to both treat and prevent migraine,” said David K. Rosen, President and CEO of eNeura. “With this round of investment led by Camden Partners Nexus, we will be able to offer patients access to a safe, effective and cost effective treatment and preventative for migraine headache.”

Following the U.S. Food and Drug Administration (FDA) clearance of sTMS for acute treatment and prevention of migraine headache in mid 2017, eNeura has launched its newest generation of TMS working with headache specialists and neurologists at headache centers across the U.S.

“eNeura is establishing the market for non-invasive treatment and prevention of migraine headache through sTMS therapy,” said Jacob Vogelstein, Managing Partner, Nexus Fund at Camden Partners. “Neuromodulation is the next great advancement in migraine treatment and prevention and we are pleased to have the opportunity to support eNeura’s commercial efforts to expand sTMS access for patients.”